Literature DB >> 24435107

Predictive value of thrombus attenuation on thin-slice non-contrast CT for persistent occlusion after intravenous thrombolysis.

J M Niesten1, I C van der Schaaf, Y van der Graaf, L J Kappelle, G J Biessels, A D Horsch, J W Dankbaar, M J A Luitse, T van Seeters, E J Smit, W P Th M Mali, B K Velthuis.   

Abstract

BACKGROUND: In stroke erythrocyte-rich thrombi are more sensitive to intravenous thrombolysis with recombinant tissue plasminogen activator (IV-rtPA) and have higher density on non-contrast CT (NCCT). We investigated the relationship between thrombus density and recanalization and whether persistent occlusions can be predicted by Hounsfield unit (HU) measurements.
METHODS: In 88 IV-rtPA-treated patients with intracranial ICA or MCA occluding thrombus and follow-up imaging, thrombus and contralateral vessel attenuation measurements were performed on thin-slice NCCT. Mean absolute and relative HU were compared between patients with persistent occlusion (modified Thrombolysis in Cerebral Infarction system, grade 0/1/2a) and recanalization (grade 2b/3). Univariate and multivariate (adjusted for stroke subtype, clot burden score, occlusion site and time to thrombolysis) odds ratios for persistent occlusion were calculated. Additional prognostic value for persistent occlusion was estimated by adding HU measurements to the area under the curve (AUC) of known determinants and calculating optimal cut-off values.
RESULTS: Patients with persistent occlusion (n = 19) had significant lower mean HU (absolute 52.2 ± 9.5, relative 1.29 ± 0.20) compared to recanalization (absolute 63.1 ± 10.7, relative 1.54 ± 0.23, both p < 0.0001). Odds ratios for persistent occlusion were 3.1 (95% confidence interval, CI 1.6-6.0) univariate and 3.1 (95% CI 1.7-5.7) multivariate per 10 absolute HU decrease and 3.2 (95% CI 1.6-6.5) univariate and 4.1 (95% CI 1.8-9.1) multivariate per 0.20 relative HU decrease. Attenuation measurements significantly increased the AUC (0.67) of the known determinants to 0.84 (absolute HU) and 0.86 (relative HU). Cut-off values of <56.5 absolute HU and <1.38 relative HU showed optimal predictive values for persistent occlusion.
CONCLUSIONS: Thrombus density is related to recanalization rate. Lower absolute and relative HU are independently related to persistent occlusion and HU measurements significantly increase discriminative performances of known recanalization determinants.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24435107     DOI: 10.1159/000357420

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  18 in total

Review 1.  Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome: a systematic review.

Authors:  Waleed Brinjikji; Sharon Duffy; Anthony Burrows; Werner Hacke; David Liebeskind; Charles B L M Majoie; Diederik W J Dippel; Adnan H Siddiqui; Pooja Khatri; Blaise Baxter; Raul Nogeuira; Matt Gounis; Tudor Jovin; David F Kallmes
Journal:  J Neurointerv Surg       Date:  2016-05-10       Impact factor: 5.836

Review 2.  Clot Pathophysiology: Why Is It Clinically Important?

Authors:  Patrick A Brouwer; Waleed Brinjikji; Simon F De Meyer
Journal:  Neuroimaging Clin N Am       Date:  2018-09-15       Impact factor: 2.264

3.  Effect of Thrombin and Incubation Time on Porcine Whole Blood Clot Elasticity and Recombinant Tissue Plasminogen Activator Susceptibility.

Authors:  Chadi Zemzemi; Matthew Phillips; Deborah C Vela; Nicole A Hilvert; John M Racadio; Kenneth B Bader; Kevin J Haworth; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2022-05-26       Impact factor: 3.694

4.  Heterogeneity between proximal and distal aspects of occlusive thrombi on pretreatment imaging in acute ischemic stroke.

Authors:  Tetsuya Hashimoto; Takenobu Kunieda; Tristan Honda; Fabien Scalzo; Latisha K Sharma; Jason D Hinman; Neal M Rao; May Nour; Mersedeh Bahr-Hosseini; Jeffrey L Saver; Radoslav Raychev; David S Liebeskind
Journal:  Neuroradiol J       Date:  2021-10-05

5.  Wake-Up Stroke versus Stroke with Known Onset Time: Clinical and Multimodality CT Imaging Characteristics.

Authors:  Jan W Dankbaar; Henri P Bienfait; Coen van den Berg; Edwin Bennink; Alexander D Horsch; Tom van Seeters; Irene C van der Schaaf; L Jaap Kappelle; Birgitta K Velthuis
Journal:  Cerebrovasc Dis       Date:  2018-05-17       Impact factor: 2.762

6.  Automated Entire Thrombus Density Measurements for Robust and Comprehensive Thrombus Characterization in Patients with Acute Ischemic Stroke.

Authors:  Emilie M M Santos; Wiro J Niessen; Albert J Yoo; Olvert A Berkhemer; Ludo F Beenen; Charles B Majoie; Henk A Marquering
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

7.  Value of thrombus imaging in predicting the outcomes of patients with large-vessel occlusive strokes after endovascular therapy.

Authors:  Shuang-Jiao Huang; Shan-Shan Diao; Yue Lu; Tan Li; Lu-Lu Zhang; Yi-Ping Ding; Qi Fang; Xiu-Ying Cai; Zhuan Xu; Yan Kong
Journal:  Neurol Sci       Date:  2020-02-21       Impact factor: 3.307

Review 8.  Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome.

Authors:  Seán Fitzgerald; Oana M Mereuta; Karen M Doyle; Daying Dai; Ramanathan Kadirvel; David F Kallmes; Waleed Brinjikji
Journal:  J Neurosurg Sci       Date:  2018-12-05       Impact factor: 2.279

9.  Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.

Authors:  Grant Mair; Rüdiger von Kummer; Zoe Morris; Anders von Heijne; Nick Bradey; Lesley Cala; André Peeters; Andrew J Farrall; Alessandro Adami; Gillian Potter; Geoff Cohen; Peter A G Sandercock; Richard I Lindley; Joanna M Wardlaw
Journal:  Neurology       Date:  2015-12-09       Impact factor: 9.910

10.  Effect of X-Ray Attenuation of Arterial Obstructions on Intravenous Thrombolysis and Outcome after Ischemic Stroke.

Authors:  Grant Mair; Rüdiger von Kummer; Richard I Lindley; Peter A G Sandercock; Joanna M Wardlaw
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.